A recent study by the Cardiocentro Ticino Foundation has revealed that P2Y12 inhibitors are more effective at reducing the risk of heart attacks and strokes compared to aspirin alone in people with coronary artery disease.
Importantly, this benefit comes without an increased risk of major bleeding, making P2Y12 inhibitors a promising alternative for long-term heart health management.
For decades, aspirin has been the standard preventive treatment for patients with blood vessel disease. After an acute coronary syndrome, patients typically undergo dual antiplatelet therapy (DAPT), which combines aspirin with a P2Y12 inhibitor for a limited time before transitioning to lifelong aspirin use.
However, earlier research had hinted at a mild benefit of using clopidogrel, a type of P2Y12 inhibitor, over aspirin for heart disease prevention.
This new study takes a closer look at the long-term effects of P2Y12 inhibitors (clopidogrel, prasugrel, or ticagrelor) compared to aspirin in patients with established coronary artery disease.
The research analyzed data from 24,325 participants, including 12,178 who received a P2Y12 inhibitor and 12,147 who took aspirin. Participants had an average age of 64.3 years, with 21.7% being women, and the treatments lasted for an average of 557 days.
The results showed that P2Y12 inhibitors significantly reduced the risk of heart attacks and strokes. Specifically, the study found a 12% overall reduction in the risk of these events compared to aspirin.
This improvement was largely driven by a 23% reduction in the risk of heart attacks among patients taking P2Y12 inhibitors.
Not only were P2Y12 inhibitors more effective, but they also demonstrated a better safety profile.
While the overall risk of major bleeding was similar between the two treatments, patients taking P2Y12 inhibitors experienced fewer cases of gastrointestinal bleeding and hemorrhagic stroke compared to those on aspirin alone.
These findings highlight the potential of P2Y12 inhibitors as a safer and more effective long-term treatment option for people with coronary artery disease.
By reducing the risk of heart attacks and strokes without increasing bleeding complications, these medications could change how heart disease is managed in the future.
The study, led by Professor Marco Valgimigli, provides robust evidence to support the use of P2Y12 inhibitors in appropriate patients and opens the door to rethinking standard treatment practices for coronary artery disease.
For patients and doctors, this offers hope for improved outcomes with fewer risks.
The research underscores the importance of continued exploration into better therapies for heart disease, which remains a leading cause of death worldwide.
If you care about health, please read studies about the benefits of low-dose lithium supplements, and what we know about egg intake and heart disease.
For more health information, please see recent studies about potatoes and high blood pressure, and results showing 6 best breads for people with heart disease.
Copyright © 2025 Knowridge Science Report. All rights reserved.
